Previous 10 | Next 10 |
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Simona King, chief financial officer of Passage B...
Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Passage Bio, Inc. (NASDAQ: PASG) (“Passage” or the “Company”). The investigations concern whether certain of the Passage’s officers and directors...
PHILADELPHIA, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted inducement awards to new employees. Pa...
The following slide deck was published by Passage Bio, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Passage Bio, Inc. 2022 Q2 - Results - Earnings Call Presentation
PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc . (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that the first patient has been dosed in the global Ph...
Passage Bio, Inc. (PASG) Q2 2022 Earnings Conference Call August 04, 2022, 08:30 AM ET Company Participants Stuart Henderson - VP of Corporate Development and IR Edgar Cale - Interim CEO Simona King - CFO Mark Forman - Chief Medical Officer Conference C...
PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Simona King, chief financial officer of Passage Bio, w...
Passage Bio press release ( NASDAQ: PASG ): Q2 GAAP EPS of -$0.73 beats by $0.09 . Cash, cash equivalents and marketable securities were $239.3M as of June 30, 2022, compared to $267.1M as of March 31, 2022. The company expects current cash and cash equivalent...
Advanced Imagine-1 clinical trial for GM1 gangliosidosis to recruitment of final cohort, Cohort 4, in dose-ascending phase of study following recommendation by Independent Data Monitoring Committee Presented encouraging longer-term clinical and biomarker data from Cohort 1 in Im...
PHILADELPHIA, July 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:3...
News, Short Squeeze, Breakout and More Instantly...
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Plan to initiate dosing of FTD-C9orf72 patients in 1H 2025 PHILADELPHIA, July 16, 2024 (...
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will present at ...
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of i...